An interventional study of Givinostat in Juvenile Idiopathic Arthritis, sponsored by Italfarmaco. Terminated at 1 site in Czechia. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-04-06.
Sponsored by Italfarmaco · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Arthritis, Juvenile with a site in Czechia — 3 open to participants now, 5 under way, 5 of them phase 3. Arthritis, Juvenile · Czechia.
Among the 14 studies in Arthritis, Juvenile with a site in Czechia, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2011, is the only one with no phase, and was the 6th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →3 of the 14 studies in Arthritis, Juvenile with a site in Czechia are open now. Recruiting first, the newest first:
Alfasigma S.p.A. · Sites in Czechia, Belgium, France and 6 more countries
Ages 8–18
Bristol-Myers Squibb · Sites in Czechia, United States, Brazil and 8 more countries
Ages 5–17
Eli Lilly and Company · Sites in Czechia, Argentina, Australia and 17 more countries
Ages 1–18
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 52 across 230 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 101 across the 13 interventional studies, 849 across the 1 observational. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 10 most frequent:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Italfarmaco has 3 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
1 of the studies in Arthritis, Juvenile with a site in Czechia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Arthritis, Juvenile with a site in Czechia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective of the study:
the purpose of this extension study was to determine the safety of Givinostat in a long term treatment of patients who participated in DSC/08/2357/36 study with good results (clinical benefit at least pediACR30 response);
Givinostat is expected to exert a clinically relevant therapeutic effect on polyarticular JIA through the inhibition of the production/release of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNFα, which are involved in the pathogenesis of the arthritic process.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014
Drug: Givinostat
ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients
Also known as: ITF2357
Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AE) of Interest
During the entire study period it was reported only one adverse event considered not drug related by the investigator (Mild flu at week 107 of study treatment). No action was taken and the patient recovered spontaneously
Time frame: Through end of treatment, up to 108 weeks.
Number of Patients Who Maintained PedACR30 Response
This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR30 is defined as at least a 30% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)
Time frame: At weeks 48, 60 and 108
Number of Patients Who Reached PedACR70 Response
This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR70 is defined as at least a 70% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)
Time frame: At weeks 48, 60 and 108
| Milestone | Givinostat |
|---|---|
| Started | 1 |
| Completed | 1 |
| Not completed | 0 |
During the entire study period it was reported only one adverse event considered not drug related by the investigator (Mild flu at week 107 of study treatment). No action was taken and the patient recovered spontaneously
| participants | Givinostat |
|---|---|
| non serious AE | 1 |
| serious AE | 0 |
This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR30 is defined as at least a 30% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)
| participants | Givinostat |
|---|---|
| week 48 | 1 |
| week 60 | 0 |
| week 108 | 1 |
This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR70 is defined as at least a 70% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)
| participants | Givinostat |
|---|---|
| week 48 | 0 |
| week 60 | 1 |
| week 108 | 0 |
Collected over Through end of treatment, up to 108 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Givinostat | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Givinostat |
|---|---|
| InfluenzaInfections and infestations | 1/1 |
| Age, Categorical(Participants) | Givinostat |
|---|---|
| <=18 years | 1 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Givinostat |
|---|---|
| Female | 1 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Givinostat |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Givinostat |
|---|---|
| Czechia | 1 |
Ran from Dec 2011 to primary completion in Jan 2014, 24 months.
Results were first posted in Apr 2021, 7 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat